Top-News
Donnerstag,
20.02.2020 08:00
von
GlobeNewswire
| Aufrufe: 838
ContextVision Sees Strong Momentum in 2019 Across Medical Imaging and Digital Pathology Sectors
Verschiedene Medikamente in Tabletten- und Kapselform. (Symbolbild)
© pixabay.com/CC0
https://pixabay.com
STOCKHOLM – February 20, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today announced solid sales in Q4 to close out a record year for the company. With sales growth across its medical imaging offerings and patent approval for its unique method for high-quality digital pathology data generation, this past quarter has set a strong foundation for the future of the company.
Sales in the fourth quarter ended at 28.1 MSEK, a small increase compared to the fourth quarter in 2018. Sales in 2019 ended at 95.3 MSEK. Operating result was -4.6 MSEK in Q4 and 10.1 MSEK for 2019. This with a strong EBITDA reaching 8.1 MSEK in Q4 and 28.2 MSEK for 2019.
Medical Imaging
Altumira™, ContextVision’s latest AI-based product for image enhancement in radiography, was a strong driver of sales, with a 55 percent increase in radiography compared to the corresponding quarter in 2018.
In Q4, ContextVision also announced the market launch for its next-generation ultrasound product, Rivent™, which has now entered the product development phase. The launch was well received among potential customers and the official product release is targeted for the second quarter of 2020.
Subsequent events after year end in terms of multiple signed contracts will have positive effects on revenue in 2020.
“In Q4, we continued to strengthen our brand with new product initiatives and we also made important advancements in our partnerships with existing and prospective medical imaging customers. This success gives us great optimism about further sales growth in the sector” said Fredrik Palm, CEO of ContextVision.
Digital Pathology
ContextVision is progressing towards the release of the first digital pathology product, INIFY Prostate Screening. The product development timeline is extended to ensure INIFY meets the high demands in quality and robustness required by ContextVision.
The company also achieved a major milestone in Q4 with its first digital pathology patent for its unique and objective data-generation method, Master Annotation. This Master Annotation method is the cornerstone of INIFY Prostate Screening, the company’s first decision support product for screening on prostate biopsy images. This powerful AI-based software outlines and quantifies suspected cancerous areas in a series of prostate biopsies and sorts them in a worst-first order. Beta-testing for the product is currently ongoing and ContextVision is dedicated to set the CE mark, and make the first product commercially available as soon as all quality measures are met.
Fredrik Palm, chief executive officer, ContextVision, said:
“2019 has been a progressive year for us both in sales and investment for our future growth. We focused heavily on R&D activities while continuing to build our leading brand within medical imaging and establishing brand awareness within digital pathology. It’s our mission to offer powerful software solutions to support healthcare professionals in the daily decision-making process to deliver the best possible patient care. This past quarter and 2019 as a whole, has been a great testament to our progress towards achieving that, and I’m looking forward to what we’ll accomplish in the coming years".
About ContextVision
ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. As the global market leader within image enhancement, ContextVision is a software partner to leading medical imaging manufacturers around the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
As an industry pioneer for more than 30 years, ContextVision has developed state-of-the-art capabilities in the latest artificial intelligence technologies. By combining these with its well-established GOP technology, the company is introducing a new generation of image enhancement products. ContextVision are determined to expand by approaching the growing digital pathology market with new AI-based decision support tools for pathologists.
The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.
For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or visit www.contextvision.com.
This information is information that ContextVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on February 20, 2020.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Attachment
Werbung
Mehr Nachrichten zur CONTEXTVISION SK 0,25 Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
